The pharmacological properties of RNA therapeutics and vaccines are influenced by their chemistry, formulation, dosage and host genetic variation (‘pharmacogenomics’). These pharmacological attributes are fundamental for the therapeutic efficacy and safety of RNA modalities, yet these interactions are not well understood and characterised. This research cluster aims to focus on understanding these pharmacogenomic interactions by leveraging on Singapore’s genetically diverse population to study pharmacogenomics with the goal of ultimately developing personalised RNA medicines, that are optimised for diverse patient populations.
